@article{10.37349/etat.2025.1002353,
abstract = {Fibroblast growth factor receptor 1 (FGFR1) is crucial in the progression of various cancers, participating in the processes of cell proliferation, survival, and differentiation. FGFR1 plays a role in the resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Therefore, using monoclonal antibodies and tyrosine kinase inhibitors to target FGFR1 and enhancing ICIs by modifying the tumor microenvironment and combating immune suppression represents a potential therapeutic strategy. Based on the FGFR1-related research and the active targeting strategy, we believe that modifying the surface of nanomedicines with anti-FGFR1 antibodies (such as OM-RCA-01) is an effective targeted treatment method for tumors with high expression of FGFR1. Although there have been relevant studies confirming the feasibility of this approach, there are challenges in clinical application, especially in terms of maintaining uniform quality during large-scale production. Therefore, we suggest conducting further optimization studies in the future to accelerate the clinical application of such drug delivery systems and provide more efficient and cost-effective options for tumor treatment.},
author = {Ma, Yilin and Guo, Mengqin and Liu, Yang and Huang, Zhengwei},
doi = {10.37349/etat.2025.1002353},
journal = {Exploration of Targeted Anti-tumor Therapy},
elocation-id = {1002353},
title = {Conceptualization of fibroblast growth factor receptor 1 targeting nanomedicines},
url = {https://www.explorationpub.com/Journals/etat/Article/1002353},
volume = {6},
year = {2025}
}